RU2651708C2 - Прогнозирование риска сердечно-сосудистого события и его применение - Google Patents

Прогнозирование риска сердечно-сосудистого события и его применение Download PDF

Info

Publication number
RU2651708C2
RU2651708C2 RU2014110508A RU2014110508A RU2651708C2 RU 2651708 C2 RU2651708 C2 RU 2651708C2 RU 2014110508 A RU2014110508 A RU 2014110508A RU 2014110508 A RU2014110508 A RU 2014110508A RU 2651708 C2 RU2651708 C2 RU 2651708C2
Authority
RU
Russia
Prior art keywords
risk
individual
cardiovascular
biomarkers
biomarker
Prior art date
Application number
RU2014110508A
Other languages
English (en)
Russian (ru)
Other versions
RU2014110508A (ru
Inventor
Розалинн Дайанн ДЖИЛЛ
Стивен Аларик УИЛЛЬЯМС
Алекс А.Е. СТЮАРТ
Роберт МЕЛЕР
Труди ФОРМАН
Бритта СИНГЕР
Original Assignee
Сомалоджик, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сомалоджик, Инк. filed Critical Сомалоджик, Инк.
Publication of RU2014110508A publication Critical patent/RU2014110508A/ru
Application granted granted Critical
Publication of RU2651708C2 publication Critical patent/RU2651708C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
RU2014110508A 2011-09-30 2012-09-28 Прогнозирование риска сердечно-сосудистого события и его применение RU2651708C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
US61/541,828 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (2)

Publication Number Publication Date
RU2014110508A RU2014110508A (ru) 2015-11-10
RU2651708C2 true RU2651708C2 (ru) 2018-04-23

Family

ID=47993164

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014110508A RU2651708C2 (ru) 2011-09-30 2012-09-28 Прогнозирование риска сердечно-сосудистого события и его применение

Country Status (16)

Country Link
US (3) US20130085079A1 (cg-RX-API-DMAC7.html)
EP (1) EP2761289B1 (cg-RX-API-DMAC7.html)
JP (3) JP6652781B2 (cg-RX-API-DMAC7.html)
KR (2) KR102111624B1 (cg-RX-API-DMAC7.html)
CN (4) CN103959060B (cg-RX-API-DMAC7.html)
AU (1) AU2013202112B9 (cg-RX-API-DMAC7.html)
BR (2) BR122019023720B1 (cg-RX-API-DMAC7.html)
CA (2) CA3074279C (cg-RX-API-DMAC7.html)
ES (1) ES2777002T3 (cg-RX-API-DMAC7.html)
IL (1) IL231387A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN01970A (cg-RX-API-DMAC7.html)
MX (2) MX373248B (cg-RX-API-DMAC7.html)
RU (1) RU2651708C2 (cg-RX-API-DMAC7.html)
SG (3) SG10201607331WA (cg-RX-API-DMAC7.html)
WO (1) WO2013049674A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401778B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
RU2802420C1 (ru) * 2022-11-01 2023-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития инфаркта миокарда у пациентов с коморбидной патологией - сахарным диабетом 2 типа, хронической болезнью почек и гипофункцией щитовидной железы

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2011154689A1 (en) * 2010-06-07 2011-12-15 King's College London Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
KR101857462B1 (ko) 2010-08-13 2018-05-14 소마로직, 인크. 췌장암 바이오마커 및 그것의 용도
WO2012122540A1 (en) 2011-03-10 2012-09-13 Somalogic, Inc. Aptamers for clostridium difficile diagnostics
KR102111624B1 (ko) * 2011-09-30 2020-05-18 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
CN108359711A (zh) 2012-01-27 2018-08-03 利兰斯坦福青年大学董事会 解析和定量无细胞rna的方法
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
BR112016005957A2 (pt) 2013-09-24 2017-09-26 Somalogic Inc detecção de alvo multiaptâmero
SG11201607487UA (en) * 2014-03-21 2016-10-28 Sanofi Aventis Deutschland New markers for the assessment of the risk for development of a cardiovascular disorder
US20170102396A1 (en) * 2014-06-05 2017-04-13 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
CA2961340C (en) * 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
EP3320132A4 (en) * 2015-07-10 2018-11-21 West Virginia University Markers of stroke and stroke severity
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
EP4513191A3 (en) * 2016-02-08 2025-06-04 SomaLogic Operating Co., Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
WO2017156310A1 (en) * 2016-03-09 2017-09-14 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
US20190154708A1 (en) * 2016-04-06 2019-05-23 Nestec S.A. Biomarkers for predicting degree of weight loss
CN108882878B (zh) 2016-04-15 2021-04-23 欧姆龙株式会社 生物体信息分析装置、系统以及程序
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
JP7058331B2 (ja) 2017-12-13 2022-04-21 エフ．ホフマン－ラ ロシュ アーゲー 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
CN112888948A (zh) * 2018-08-10 2021-06-01 豪夫迈·罗氏有限公司 用于评定Afib相关性脑卒中的CES-2（羧酸酯酶-2）
US20210327540A1 (en) * 2018-08-17 2021-10-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
KR20210047304A (ko) * 2018-08-22 2021-04-29 에프. 호프만-라 로슈 아게 심방 세동 평가에서 순환 spon-1 (스폰딘-1)
CN113287019A (zh) * 2018-10-31 2021-08-20 卡洛斯三世国家心血管研究中心 亚临床动脉粥样硬化的生物标志物
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
CA3126990A1 (en) 2019-02-14 2020-08-20 Maneesh Jain Methods and systems for determining a pregnancy-related state of a subject
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
WO2021046074A1 (en) * 2019-09-03 2021-03-11 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US20220390468A1 (en) * 2019-11-06 2022-12-08 National University Corporation Kagawa University Heart failure marker
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
EP4153995A4 (en) * 2020-05-19 2024-10-23 Falcon Bioscience, LLC DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION ENGAGEMENT
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition
AU2021364805A1 (en) * 2020-10-20 2023-05-18 Somalogic Operating Co., Inc. Cardiovascular event risk prediction
WO2022165393A1 (en) * 2021-02-01 2022-08-04 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
WO2023023748A1 (en) * 2021-08-26 2023-03-02 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
WO2024226519A2 (en) * 2023-04-24 2024-10-31 Google Llc Deep learning-based photoplethysmography model for cardiovascular risk prediction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
WO2010142713A1 (en) * 2009-06-09 2010-12-16 Gendiag.Exe, S.L. Risk markers for cardiovascular disease
US20110003707A1 (en) * 2009-06-08 2011-01-06 Singulex, Inc. Highly Sensitive Biomarker Panels

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP2004500100A (ja) * 2000-03-06 2004-01-08 スミスクライン・ビーチャム・コーポレイション 新規化合物
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP3425059A1 (en) * 2002-05-09 2019-01-09 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP2008523394A (ja) * 2004-12-10 2008-07-03 ユニヴァーシティー オブ メリーランド， バルティモア 炎症及び肥満症における血清アミロイドａタンパク質
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
WO2007088849A1 (ja) * 2006-01-31 2007-08-09 Mitsubishi Kagaku Iatron, Inc. 播種性血管内凝固症候群の病態把握方法
WO2007103568A2 (en) * 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
SI2185198T1 (sl) * 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
JP2011510297A (ja) * 2008-01-18 2011-03-31 バトリックス・メディカル・インコーポレイテッド 動脈瘤のための診断バイオマーカー
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010019574A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
CN102203616A (zh) * 2008-10-07 2011-09-28 B.R.A.H.M.S有限公司 用于预测初次不利事件的生物标志物
AU2010260152A1 (en) * 2009-06-15 2012-02-02 Cardiodx, Inc. Determination of coronary artery disease risk.
JP2013509588A (ja) 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
JP2013513387A (ja) * 2009-12-09 2013-04-22 アヴィール インコーポレイテッド 循環器疾患の診断と分類のためのバイオマーカーアッセイ
CA2808233C (en) * 2010-03-03 2017-07-11 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
KR102111624B1 (ko) * 2011-09-30 2020-05-18 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
ES2779698T3 (es) * 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
US20110003707A1 (en) * 2009-06-08 2011-01-06 Singulex, Inc. Highly Sensitive Biomarker Panels
WO2010142713A1 (en) * 2009-06-09 2010-12-16 Gendiag.Exe, S.L. Risk markers for cardiovascular disease

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
RU2802420C1 (ru) * 2022-11-01 2023-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития инфаркта миокарда у пациентов с коморбидной патологией - сахарным диабетом 2 типа, хронической болезнью почек и гипофункцией щитовидной железы
RU2819657C1 (ru) * 2023-11-23 2024-05-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования острых сосудистых событий у пациентов с Ph-негативными миелопролиферативными новообразованиями на основании уровня костномозговой экспрессии MMP9

Also Published As

Publication number Publication date
JP6652781B2 (ja) 2020-02-26
BR112014007214A2 (pt) 2017-04-04
BR122019023720B1 (pt) 2023-01-24
SG11201400904SA (en) 2014-04-28
EP2761289B1 (en) 2020-02-12
JP2020024216A (ja) 2020-02-13
WO2013049674A1 (en) 2013-04-04
AU2013202112B9 (en) 2015-10-22
CA3074279C (en) 2021-10-19
MX373248B (es) 2020-05-11
IL231387A (en) 2017-12-31
IN2014CN01970A (cg-RX-API-DMAC7.html) 2015-05-29
US20200166523A1 (en) 2020-05-28
CN114518458A (zh) 2022-05-20
KR102248900B1 (ko) 2021-05-07
JP2018159713A (ja) 2018-10-11
CN103959060A (zh) 2014-07-30
MX2014003153A (es) 2014-04-30
AU2013202112A1 (en) 2013-05-02
JP6546318B2 (ja) 2019-07-17
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
JP2014528576A (ja) 2014-10-27
KR20200055804A (ko) 2020-05-21
CA2847903C (en) 2020-10-27
CN107422126A (zh) 2017-12-01
KR20140084106A (ko) 2014-07-04
CA3074279A1 (en) 2013-04-04
AU2013202112B2 (en) 2015-09-24
CN107102151A (zh) 2017-08-29
RU2014110508A (ru) 2015-11-10
JP6917432B2 (ja) 2021-08-11
KR102111624B1 (ko) 2020-05-18
SG10201607331WA (en) 2016-11-29
EP2761289A1 (en) 2014-08-06
BR112014007214B1 (pt) 2022-08-16
BR122019023720A8 (pt) 2022-07-26
HK1247666A1 (zh) 2018-09-28
SG10201906900QA (en) 2019-09-27
BR122019023720A2 (cg-RX-API-DMAC7.html) 2017-04-04
IL231387A0 (en) 2014-04-30
CN103959060B (zh) 2017-05-17
ES2777002T3 (es) 2020-08-03
EP2761289A4 (en) 2015-08-12
BR112014007214A8 (pt) 2022-07-26
MX2020004617A (es) 2020-08-06
NZ622118A (en) 2016-01-29
US20150168423A1 (en) 2015-06-18
ZA201401778B (en) 2018-08-25
US20130085079A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
RU2651708C2 (ru) Прогнозирование риска сердечно-сосудистого события и его применение
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
JP7712913B2 (ja) 心血管リスク／イベントの予測及びその使用
WO2023278502A1 (en) Renal health determination and uses thereof
US20240255524A1 (en) Renal Insufficiency Prediction and Uses Thereof
AU2015249162B2 (en) Cardiovascular risk event prediction and uses thereof
HK40073398A (en) Cardiovascular risk event prediction and uses thereof
HK1236619A1 (en) Cardiovascular risk event prediction and uses thereof
HK1247666B (zh) 心血管危险事件预测及其用途
NZ622118B2 (en) Cardiovascular risk event prediction and uses thereof